welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Mallinckrodt Comments on its BRAVE study

Mallinckrodt Comments On Its BRAVE Study

Mallinckrodt has announced the discontinuation of their Phase II clinical trial for MNK-1411, a treatment that aimed to improve muscle health by reducing muscle inflammation and modulating immune system activity.

While these setbacks are hard to hear, we share Mallinckrodt’s optimism for the numerous ongoing Duchenne trials. We appreciate the Mallinckrodt team’s innovation, diligence, effort and contribution.

We also appreciate the families and boys who participated in this trial, and their contribution to science. Click here http://bit.ly/2PYuHFQ to read Mallinckrodt’s full press release.